Skip to main content
Contact Us
Subscribe
E-Edition
60°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Archives
Best of 2025
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Candel Therapeutics
< Previous
1
2
Next >
Candel Therapeutics to Present at Upcoming Investor Conferences
May 06, 2025
From
Candel Therapeutics
Via
GlobeNewswire
Tickers
CADL
Candel Therapeutics Announces Oral Presentation of Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025
April 23, 2025
From
Candel Therapeutics
Via
GlobeNewswire
Tickers
CADL
Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients
April 01, 2025
From
Candel Therapeutics
Via
GlobeNewswire
Tickers
CADL
Candel Therapeutics Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment
March 26, 2025
From
Candel Therapeutics
Via
GlobeNewswire
Tickers
CADL
Candel Therapeutics and IDEA Pharma Announce Strategic Partnership to Advance Path-to-Market Commercialization Efforts for CAN-2409
March 20, 2025
From
Candel Therapeutics
Via
GlobeNewswire
Tickers
CADL
Candel Therapeutics Appoints Renowned Pancreatic Cancer Expert, Elizabeth M. Jaffee, M.D., to Research Advisory Board
March 18, 2025
From
Candel Therapeutics
Via
GlobeNewswire
Tickers
CADL
Candel Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights
March 13, 2025
From
Candel Therapeutics
Via
GlobeNewswire
Tickers
CADL
Candel Therapeutics Announces Positive Final Survival Data from Randomized Controlled Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
February 25, 2025
From
Candel Therapeutics
Via
GlobeNewswire
Tickers
CADL
Candel Therapeutics Provides Corporate Update and Highlights Strong Pipeline Momentum and Key Value Drivers for 2025
January 13, 2025
From
Candel Therapeutics
Via
GlobeNewswire
Tickers
CADL
Candel Therapeutics Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
December 16, 2024
From
Candel Therapeutics
Via
GlobeNewswire
Tickers
CADL
Candel Therapeutics Announces Pricing of Public Offering
December 12, 2024
From
Candel Therapeutics
Via
GlobeNewswire
Tickers
CADL
Candel Therapeutics Announces $80 Million Proposed Public Offering
December 12, 2024
From
Candel Therapeutics
Via
GlobeNewswire
Tickers
CADL
Candel Therapeutics Announces CAN-2409 Achieved Primary Endpoint in Phase 3 Prostate Cancer Trial, Showing Significantly Improved Disease-Free Survival
December 11, 2024
From
Candel Therapeutics
Via
GlobeNewswire
Tickers
CADL
Candel Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
November 14, 2024
From
Candel Therapeutics
Via
GlobeNewswire
Tickers
CADL
Candel Therapeutics to Present at Jefferies London Healthcare Conference 2024
November 07, 2024
From
Candel Therapeutics
Via
GlobeNewswire
Tickers
CADL
Candel Therapeutics to Present Preclinical Data at SITC Annual Meeting Showing Promise for CAN-3110 in Melanoma, Signaling Potential Indication Expansion Beyond Recurrent High-Grade Glioma
November 05, 2024
From
Candel Therapeutics
Via
GlobeNewswire
Tickers
CADL
Candel Therapeutics Showcases Innovative Cancer Therapy Candidates at 16th Annual International Oncolytic Virotherapy Conference (IOVC)
October 28, 2024
From
Candel Therapeutics
Via
GlobeNewswire
Tickers
CADL
Candel Therapeutics to Present Preclinical Data on Therapeutic Potential of CAN-3110 in Melanoma at SITC 2024 Annual Meeting
October 04, 2024
From
Candel Therapeutics
Via
GlobeNewswire
Tickers
CADL
Candel Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
September 03, 2024
From
Candel Therapeutics
Via
GlobeNewswire
Tickers
CADL
Candel Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
August 13, 2024
From
Candel Therapeutics
Via
GlobeNewswire
Tickers
CADL
Candel Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
June 18, 2024
From
Candel Therapeutics
Via
GlobeNewswire
Tickers
CADL
Candel Therapeutics to Join Russell 3000® Index
June 11, 2024
From
Candel Therapeutics
Via
GlobeNewswire
Tickers
CADL
FDA Grants Orphan Drug Designation for CAN-3110 for the Treatment of Recurrent High-Grade Glioma
May 30, 2024
From
Candel Therapeutics
Via
GlobeNewswire
Tickers
CADL
Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of CAN-2409 for Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment at 2024 ASCO Annual Meeting
May 23, 2024
From
Candel Therapeutics
Via
GlobeNewswire
Tickers
CADL
Candel Therapeutics to Present at the Jefferies Global Healthcare Conference
May 22, 2024
From
Candel Therapeutics
Via
GlobeNewswire
Tickers
CADL
Candel Therapeutics to Host Non-Small Cell Lung Cancer (NSCLC) R&D Breakfast Panel During 2024 ASCO Annual Meeting
May 20, 2024
From
Candel Therapeutics
Via
GlobeNewswire
Tickers
CADL
Candel Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
May 14, 2024
From
Candel Therapeutics
Via
GlobeNewswire
Tickers
CADL
Candel Therapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting
April 25, 2024
From
Candel Therapeutics
Via
GlobeNewswire
Tickers
CADL
Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer
April 11, 2024
From
Candel Therapeutics
Via
GlobeNewswire
Tickers
CADL
Candel Therapeutics Presents Preclinical Data at AACR on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid Tumors
April 09, 2024
From
Candel Therapeutics
Via
GlobeNewswire
Tickers
CADL
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.